Search Results for "Ranbaxy Launches Atorvastatin In Us"

05:52 EDT 27th May 2015 | BioPortfolio

Matching Channels

Lipitor

Lipitor was the best selling drug in 2009, with the 2009 annual sales coming in at over $5m for its company, Pfizer Inc. Lipitor is the brand name for an atorvastatin calcium medication that is pres...

Matching News

Ranbaxy launches J&J biosimilar in India

Ranbaxy has launched the first biosimilar of Johnson & Johnson’s Remicade (infliximab) in India, marking the firm’s entry into monoclonal antibodies biologics. The biosimilar, which will be ma...

FTC puts conditions on Sun Pharma’s proposed acquisition of Ranbaxy

Indian drugmakers Sun Pharmaceutical Industries Ltd. and Ranbaxy Laboratories have agreed to divest Ranbaxy’s interests in generic minocycline tablets in order to settle US Federal Trade Commission ...

UPDATE 1-Ranbaxy says Europe bars imports from antibiotic injectables unit

* Ranbaxy says sees no significant impact on business (Recasts with statements from Ranbaxy and European regulator, adds details)

EPIRUS Biopharmaceuticals Remicade Biosimilar Launches in India

Infimab (BOW015) launches one quarter ahead of schedule with commercialisation partner Ranbaxy Laboratories

Caution with Lipitor and boceprevir use

The summary of product characteristics for Lipitor (atorvastatin; Pfizer) now advises that patients who are concomitantly taking boceprevir should have a lower starting dose of atorvastatin and should...

With Ranbaxy Under Belt, Sun Eyes Fast Track Global Growth

Sun and Ranbaxy have finally combined into a single global company, but that could be just the beginning of a series of fresh challenges. Sun said it will look at growing its businesses faster than th...

Nexium Generics: Ranbaxy’s Exclusivity Loss Is Teva’s Gain

Teva’s readiness for approval prompts U.S. FDA conclusion that Ranbaxy forfeited its rights to 180-day exclusivity for AstraZeneca’s proton pump inhibitor; Ranbaxy is still making its case in cour...

FTC Clears Sun Pharma's $4B Purchase of Ranbaxy

NEW YORK (AP) — Sun Pharmaceuticals will sell the rights to one generic drug as part of its purchase of competitor Ranbaxy Laboratories, U.S. antitrust regulators said Friday.The Federal Trade Commi...

Matching PubMed Articles

Lipid-lowering efficacy of atorvastatin.

This represents the first update of this review, which was published in 2012. Atorvastatin is one of the most widely prescribed drugs and the most widely prescribed statin in the world. It is therefor...

Paradoxical effects of atorvastatin on renal tubular cells: an experimental investigation.

Atorvastatin has antioxidant activity and has been reported to increase blood antioxidant capacity. This study aimed to evaluate the effect of different doses of atorvastatin on gentamicin-induced kid...

Can atorvastatin calcium cause asymptomatic hypercalcemia?

The use of statins may have unnatural effects. A 54-year-old woman was admitted to the hospital with an incidental finding of hypercalcemia (10.8 mg/dL). There was no disease other than hyperlipidemia...

Impact of low dose atorvastatin on development of new-onset diabetes mellitus in Asian population: Three-year clinical outcomes.

High dose atorvastatin is known to be associated with new onset diabetes mellitus (NODM) in patients with high risk for developing diabetes mellitus (DM). However, low dose atorvastatin is more common...

HPLC-DAD Method for the Pharmacokinetic Interaction Study of Atorvastatin with Pioglitazone and Cholestyramine in Wistar Rats.

Carotid intima-media thickness is used as a surrogate marker for cardiovascular complications in diabetes mellitus. The combination of atorvastatin and pioglitazone was found to be effective in reduci...

Search Whole site using Google

Loading
Search BioPortfolio:
Loading
Advertisement
Advertisement
Advertisement Advertisement